|
|
Volumn 14, Issue 2, 2007, Pages 132-149
|
|
Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
HEAT SHOCK PROTEIN 90;
HYPOXIA INDUCIBLE FACTOR 1;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PROTEINASE INHIBITOR;
SOMATOMEDIN C RECEPTOR;
STAT3 PROTEIN;
VASCULOTROPIN RECEPTOR;
ANIMAL;
BREAST TUMOR;
DRUG ANTAGONISM;
DRUG RESISTANCE;
ENDOTHELIUM CELL;
FEMALE;
HUMAN;
LYMPHANGIOGENESIS;
METABOLISM;
REVIEW;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
DRUG RESISTANCE, NEOPLASM;
ENDOTHELIAL CELLS;
FEMALE;
HSP90 HEAT-SHOCK PROTEINS;
HUMANS;
HYPOXIA-INDUCIBLE FACTOR 1;
LYMPHANGIOGENESIS;
PROTEASE INHIBITORS;
PROTEIN KINASE INHIBITORS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
RECEPTOR, ERBB-2;
RECEPTOR, IGF TYPE 1;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
SRC-FAMILY KINASES;
STAT3 TRANSCRIPTION FACTOR;
|
|
EID: 34748881947
PISSN: 13406868
EISSN: None
Source Type: Journal
DOI: 10.2325/jbcs.977 Document Type: Review |
|
Times cited : (24)
|
|
References (48)
|
